Results 81 to 90 of about 2,749 (135)

Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure

Gut and Liver, 2014
Background/AimsWe investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies.Methods : Seventeen patients who failed to achieve virological ...
doaj   +1 more source

Real‐World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug‐Resistant HIV‐1 in Southeastern France

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Syrine Boujamline, Celine Boschi, Hugo Bes‐Barlandier, Christelle Tomei, Amelie Menard, Saadia Mokhtari, Isabelle Ravaux, Yacine Belkhir, Nadege Neant, Caroline Solas, Philippe Colson, Matthieu Million   +11 more
wiley   +1 more source

Dyslipidemia in chronic hepatitis B patients on tenofovir alafenamide: Facts and puzzles [PDF]

Clinical and Molecular Hepatology, 2022
Hung-Yao Lin, Tai-Chung Tseng
doaj   +1 more source

HIV and CKD in the Tenofovir Era: A Prospective Parallel-Group Cohort Study From Tanzania

Kidney Medicine
Rationale & Objective: Longitudinal research on chronic kidney disease (CKD) in sub-Saharan Africa is sparse, especially among people living with HIV (PLWH).
Nicholas L.S. Roberts, Salama Fadhil, Megan Willkens, Grace Ruselu, Bernard Desderius, Said Kanenda, Ladius Rudovick, Bazil B. Kavishe, Serena P. Koenig, Sri Lekha Tummalapalli, Myung Hee Lee, Robert N. Peck   +11 more
doaj   +1 more source

Net Renal Drug Secretion Critically Requires Significant Contribution of Basal Uptake Transporters: Perspective From Mechanistic Kidney Model Simulation and Integration of Clinical and In Vitro Data

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACT Renal clearance (CLr) is the net outcome of glomerular filtration, secretion, and reabsorption, which makes the quantitative requirements for net renal secretion difficult to infer from simple clearance models. Using a mechanistic kidney model (MechKiM), we simulated blood‐referenced CLr (CLr,b) for 30,000 virtual drugs (neutral, monoanionic ...
Toshiaki Tsuchitani, Masatoshi Tomi, Yuichi Sugiyama   +2 more
wiley   +1 more source

Renal Tubular Acidosis and Osteomalacia, Possibly Associated with Tenofovir

Turkish Journal of Nephrology, 2019
Tenofovir is one of the first-line new generation antiviral agents commonly used in chronic hepatitis B treatment. While being considered an effective and safe treatment, the most important side effect known is nephrotoxicity.
Faruk ELYİĞİT, Bengü ERKUL, Hakan YARKICI, Handan ARLI, Lütfiye Bilge ÇALIŞKAN, Harun AKAR   +5 more
doaj  

Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis

Frontiers in Pharmacology
Background and aimsThe effects of Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) on lipid profiles have been observed in chronic hepatitis B (CHB) treatment.
Yuan-Hai Zhou, Yuan-Hai Zhou, Nan Cai, Nan Cai, Yu-Xin Chen, Yu-Xin Chen, Yong-Lu Su, Yong-Lu Su, Peng Hu, Peng Hu, Peng Hu   +10 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, Volume 27, Issue 9, Page 1399-1420, September 2026.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, Volume 27, Issue 9, Page 1421-1433, September 2026.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

HIV Medicine, Volume 27, Issue 9, Page 1434-1442, September 2026.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini, Sarah Fidler, Marta Boffito, Vicky Tittle, Nicolo Girometti, Gary Whitlock, on behalf of the Dean Street Collaborative Group, Keerti Gedela, Franki Lander, Alan McOwan, Diarmuid Nugent, Sheel Patel, Sashini Payagala, Tara Suchak, Vicky Tittle, Gary Whitlock   +15 more
wiley   +1 more source